– STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2] – STOBOCLO and OSENVELT, among the first wave of biosimilars referencing PROLIA and XGEVA respectively, are commercially available in the U.S. – Celltrion further expands its portfolio, delivering cost-effective and high-quality biologic medicines to wider […]
– Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with plaque psoriasis (PsO) or psoriatic arthritis (PsA) under 60kg – The FDA previously approved STEQEYMA® 45mg/0.5mL, 90mg/mL in a single-dose prefilled syringe for subcutaneous injection, and 130mg/26mL in a single-dose vial for intravenous infusion in December 2024 – […]
· Dr. Juby Jacob-Nara brings a wealth of medical and clinical development knowledge and extensive expertise across multiple therapeutic areas and will lead medical strategy at Celltrion USA JERSEY CITY, N.J., June 2, 2025 – Celltrion USA today announced the appointment of Dr. Juby Jacob-Nara, M.D. as Senior Vice President and Chief Medical Officer. […]
– YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar[1] – Celltrion previously received interchangeability (IC) designation for YUFLYMA® (adalimumab-aaty) in prefilled syringes (20mg & 80mg); Expanded interchangeability (IC) designation applies to prefilled syringe (40mg) and autoinjectors (40mg and 80mg) INCHEON, South Korea, May 23, 2025 /– Celltrion, Inc. today announced that the U.S. Food and Drug Administration […]
– Six abstracts accepted for presentation includes post hoc analyses and real-world evidence for ZYMFENTRA® (infliximab-dyyb) – Findings reinforce clinical decision-making in long-term management of moderate-to-severe Crohn’s disease and ulcerative colitis and underscore Celltrion’s commitment to advancing scientific understanding in the field of IBD INCHEON, South Korea, April 28, 2025 — Celltrion, Inc. today announced […]
· YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar, that is now interchangeable [1] · Interchangeable designation of YUFLYMA® is supported by positive data from the Phase III interchangeability study in patients with moderate-to-severe plaque psoriasis INCHEON, South Korea, April 14, 2025 /– Celltrion, Inc. today announced that the U.S. Food and […]